Measuring oxygen levels in muscle tissue using a nanosensor

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to validate the use of an electrochemical nanosensor for measuring oxygen levels in the muscle tissue of patients with mitochondrial myopathy (MM) and healthy volunteers. Participants will undergo a handgrip exercise while the nanosensor is placed in their forearm to assess muscle oxygen levels and pain. The study seeks to establish reliable biomarkers that can reflect the severity and progression of MM, which is crucial for evaluating new treatments. The data collected may enhance future diagnostic and therapeutic strategies for mitochondrial diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion Criteria for Healthy Controls

  1. Males and females, between the ages of 18 and 65 years, inclusive
  2. Provide informed consent for study participation; able to understand and complete the protocol
  3. Able to ambulate independently
  4. Able to perform bicycle ergometry

Inclusion Criteria for Mitochondrial Myopathy (MM) Cases

1. Males and females, between the ages of 18 and 65 years, inclusive
2. Provide informed consent for study participation; able to understand and complete the protocol
3. Genetically-confirmed MM as defined by a diagnosis of primary mitochondrial disease (PMD) with predominant symptoms of myopathy as expressed by exercise intolerance and muscle weakness and fatigue.
4. Previously enrolled (or will enroll) in Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) study #08-006177 (Falk, PI) or CHOP IRB #16-013364 (Zolkipli, PI)
5. Able to ambulate independently
6. Able to perform bicycle ergometry

Exclusion Criteria:

Subjects will be excluded if any of the following apply:

1. Unable to provide informed consent and complete all study procedures, including ergometry
2. Non-ambulatory or unable to ambulate independently
3. Pregnant
4. Within 1 month of a recent hospital admission due to acute illness
5. Have severe cardiac disease as defined by an ejection fraction of less than 35% and New York Heart Association Functional Classification Class III; or severe pulmonary disease as defined by the need for supplemental O2 therapy or daytime ventilatory support
6. Have a tracheostomy
7. Have a known bleeding disorder and/or family history (first-degree relative) with a known bleeding disorder
8. Daily intake of aspirin or any other anti-platelet therapy which cannot be temporarily discontinued for medical reasons
9. a) Have known or suspected congenital or acquired immune deficiency; b) concurrent use of immunosuppressive drugs, including corticosteroids; c) past history of recurrent (more than 6 times per year) severe (required hospitalization) skin or soft tissue infections; d) history of infection or delayed wound healing after surgery or biopsy; e) known history of neutropenia with absolute neutrophil count less than 500/mm3
10. Undergo chronic steroid treatment as defined by daily oral intake (for more than 1 month) or have existing untreated endocrinopathies, such as hypothyroidism that caused acquired myopathy
11. Prone to hypertrophic scars and keloids
12. Have any other known inherited myopathy, such as Duchenne muscular dystrophy or congenital myopathy
13. Known allergy to lidocaine
14. Have a cognitive impairment that may prevent the ability to complete study procedures
15. Unable to comply with the requirements of the study protocol and/or unsuitable for the study for any reason, in the opinion of the principal investigator
16. Individuals from vulnerable populations (e.g., prisoners/detainees)
17. Participants who are unable to speak and/or read English (as participants will be required to be proficient to complete study procedures)
18. Employed by the U.S. Department of Defense, including U.S. military personnel

Where it's running

• The Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Zarazuela Zolkipli-Cunningham, MBChB, MRCP — Children's Hospital of Philadelphia
• Study coordinator: Zarazuela Zolkipli-Cunningham, MBChB, MRCP
• Email: MitoMyopathyResearch@chop.edu
• Phone: 267-426-1986

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for adults with TK2 deficiency using Doxecitin and Doxribthymine

  This study is testing if a new treatment called Doxecitin and Doxribthymine can help adults with TK2 deficiency feel better and improve their condition.

  Recruiting Phase 2 Hospital Universitario 12 de Octubre · Madrid, Madrid · NCT06754098

• Effects of passive exercise on mitochondrial diseases

  This study is testing how different types of exercise, including passive exercise, affect people with mitochondrial diseases compared to healthy individuals.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT05569122

• Global registry for mitochondrial disorders

  This study is creating a global database for mitochondrial disorders to help understand these diseases better and improve future treatments for patients.

  Recruiting at 34 sites LMU Klinikum · Innsbruck and 33 other locations · NCT05554835

• Home-based personalized training and video consultations for mitochondrial myopathy patients

  This study tests whether a personalized training program and video consultations can help people with mitochondrial myopathy improve their health and quality of life.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice, Alpes Maritimes · NCT05346627

• Using N-acetylcysteine to treat patients with a specific mitochondrial mutation and low brain glutathione levels

  This study is testing if different doses of N-acetylcysteine can help improve brain function in people with a specific mitochondrial mutation and low levels of a brain chemical called glutathione.

  Recruiting Phase 1 Columbia University · New York, New York · NCT05241262

• Understanding infections in mitochondrial disease

  This study is trying to see how genetic factors affect the health of people with mitochondrial disease during infections, by looking at their blood samples and health history.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04419870

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.